These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 15897955)

  • 21. The development of effective biomarkers for Alzheimer's disease: a review.
    Henry MS; Passmore AP; Todd S; McGuinness B; Craig D; Johnston JA
    Int J Geriatr Psychiatry; 2013 Apr; 28(4):331-40. PubMed ID: 22674539
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neuroimaging and the search for a cure for Alzheimer disease.
    Petrella JR
    Radiology; 2013 Dec; 269(3):671-91. PubMed ID: 24261497
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biochemical and Radiological Markers of Alzheimer's Disease Progression.
    Dziedzic T; Pera J; Klimkowicz-Mrowiec A; Mroczko B; Slowik A
    J Alzheimers Dis; 2016; 50(3):623-44. PubMed ID: 26757184
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of biomarkers in clinical trials for Alzheimer disease.
    Thal LJ; Kantarci K; Reiman EM; Klunk WE; Weiner MW; Zetterberg H; Galasko D; Praticò D; Griffin S; Schenk D; Siemers E
    Alzheimer Dis Assoc Disord; 2006; 20(1):6-15. PubMed ID: 16493230
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The critical need for defining preclinical biomarkers in Alzheimer's disease.
    Fiandaca MS; Mapstone ME; Cheema AK; Federoff HJ
    Alzheimers Dement; 2014 Jun; 10(3 Suppl):S196-212. PubMed ID: 24924671
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of treatment effects in Alzheimer's and other neurodegenerative diseases by MRI and MRS.
    Mueller SG; Schuff N; Weiner MW
    NMR Biomed; 2006 Oct; 19(6):655-68. PubMed ID: 16986115
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NIA-AA staging of preclinical Alzheimer disease: discordance and concordance of CSF and imaging biomarkers.
    Vos SJB; Gordon BA; Su Y; Visser PJ; Holtzman DM; Morris JC; Fagan AM; Benzinger TLS
    Neurobiol Aging; 2016 Aug; 44():1-8. PubMed ID: 27318129
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Introduction to special issue: Overview of Alzheimer's Disease Neuroimaging Initiative.
    Weiner MW; Veitch DP
    Alzheimers Dement; 2015 Jul; 11(7):730-3. PubMed ID: 26194308
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Accurate Prediction of Conversion to Alzheimer's Disease using Imaging, Genetic, and Neuropsychological Biomarkers.
    Dukart J; Sambataro F; Bertolino A
    J Alzheimers Dis; 2016; 49(4):1143-59. PubMed ID: 26599054
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of neuroimaging modalities for the prediction of conversion from mild cognitive impairment to Alzheimer's dementia.
    Trzepacz PT; Yu P; Sun J; Schuh K; Case M; Witte MM; Hochstetler H; Hake A;
    Neurobiol Aging; 2014 Jan; 35(1):143-51. PubMed ID: 23954175
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Critical Comparison of Different Biomarkers for Alzheimer's Disease in a Clinical Setting.
    Weise D; Tiepolt S; Awissus C; Hoffmann KT; Lobsien D; Kaiser T; Barthel H; Sabri O; Gertz HJ
    J Alzheimers Dis; 2015; 48(2):425-32. PubMed ID: 26402006
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Amyloid imaging as a surrogate marker in clinical trials in Alzheimer's disease.
    Scheinin NM; Scheinin M; Rinne JO
    Q J Nucl Med Mol Imaging; 2011 Jun; 55(3):265-79. PubMed ID: 21532540
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is amyloid-β harmful to the brain? Insights from human imaging studies.
    Jagust W
    Brain; 2016 Jan; 139(Pt 1):23-30. PubMed ID: 26614753
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Magnetic resonance imaging in Alzheimer's Disease Neuroimaging Initiative 2.
    Jack CR; Barnes J; Bernstein MA; Borowski BJ; Brewer J; Clegg S; Dale AM; Carmichael O; Ching C; DeCarli C; Desikan RS; Fennema-Notestine C; Fjell AM; Fletcher E; Fox NC; Gunter J; Gutman BA; Holland D; Hua X; Insel P; Kantarci K; Killiany RJ; Krueger G; Leung KK; Mackin S; Maillard P; Malone IB; Mattsson N; McEvoy L; Modat M; Mueller S; Nosheny R; Ourselin S; Schuff N; Senjem ML; Simonson A; Thompson PM; Rettmann D; Vemuri P; Walhovd K; Zhao Y; Zuk S; Weiner M
    Alzheimers Dement; 2015 Jul; 11(7):740-56. PubMed ID: 26194310
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biomarkers for preclinical Alzheimer's disease.
    Tan CC; Yu JT; Tan L
    J Alzheimers Dis; 2014; 42(4):1051-69. PubMed ID: 25024325
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of 7- and 19-month-old Tg2576 mice using multimodal in vivo imaging: limitations as a translatable model of Alzheimer's disease.
    Luo F; Rustay NR; Ebert U; Hradil VP; Cole TB; Llano DA; Mudd SR; Zhang Y; Fox GB; Day M
    Neurobiol Aging; 2012 May; 33(5):933-44. PubMed ID: 20961663
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FDG-PET and amyloid-PET imaging: the diverging paths.
    Perani D
    Curr Opin Neurol; 2014 Aug; 27(4):405-13. PubMed ID: 24927239
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long night's journey into the day: amyloid-β imaging in Alzheimer's disease.
    Villemagne VL; Rowe CC
    J Alzheimers Dis; 2013; 33 Suppl 1():S349-59. PubMed ID: 22710919
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The dynamic marker hypothesis of Alzheimer's disease and its implications for clinical imaging.
    Cavedo E; Frisoni GB
    Q J Nucl Med Mol Imaging; 2011 Jun; 55(3):237-49. PubMed ID: 21532538
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.